SPEC vs. TSTL, BVC, AKR, CNSL, ODX, CTEC, AMS, ARIX, CIR, and BVXP
Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), Omega Diagnostics Group (ODX), ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), Arix Bioscience (ARIX), Circassia Group (CIR), and Bioventix (BVXP). These companies are all part of the "medical" sector.
INSPECS Group vs. Its Competitors
INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
In the previous week, Tristel had 2 more articles in the media than INSPECS Group. MarketBeat recorded 2 mentions for Tristel and 0 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.00 beat Tristel's score of -0.53 indicating that INSPECS Group is being referred to more favorably in the media.
Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.
67.8% of INSPECS Group shares are owned by institutional investors. Comparatively, 50.4% of Tristel shares are owned by institutional investors. 25.6% of INSPECS Group shares are owned by company insiders. Comparatively, 4.9% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Tristel has a consensus price target of GBX 400, indicating a potential downside of 1.64%. Given Tristel's stronger consensus rating and higher probable upside, analysts plainly believe Tristel is more favorable than INSPECS Group.
INSPECS Group has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, Tristel has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.
Tristel has a net margin of 15.47% compared to INSPECS Group's net margin of -2.10%. Tristel's return on equity of 20.43% beat INSPECS Group's return on equity.
INSPECS Group pays an annual dividend of GBX 1 per share and has a dividend yield of 2.3%. Tristel pays an annual dividend of GBX 13 per share and has a dividend yield of 3.2%. INSPECS Group pays out -24.8% of its earnings in the form of a dividend. Tristel pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
Tristel beats INSPECS Group on 11 of the 17 factors compared between the two stocks.
Get INSPECS Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INSPECS Group Competitors List
Related Companies and Tools
This page (LON:SPEC) was last updated on 7/16/2025 by MarketBeat.com Staff
Free SPEC Stock Alerts